STING1 and neoplasm: Research priorities should include: dynamic changes in pathway activity in different molecular subtypes (Luminal A/B), how tumor-stromal cell crosstalk affects pathway function, developing combination therapies based on pathway status such as sequential STING agonist and immune checkpoint inhibitor or AKT inhibitor use.